Rethinking Neurodegenerative Disease Treatment: Target Multiple Pathological Proteins, Not Just One
Nearly all major neurodegenerative diseases – from Alzheimer’s to Parkinson’s – are defined and diagnosed by the presence of one of four proteins that have gone rogue: tau, amyloid-beta (Aβ), alpha-synuclein (α-syn), or TDP-43. As such, investigational drugs and studies aimed at preventing or slowing the disease often hone in on just one of these respective proteins. However, targeting multiple proteins—known as “proteinopathies”—at once may be the real key, according to a recent study published in Brain by Penn Medicine researchers.
ADCC IN THE NEWS
12/21/18Methods to diagnose Alzheimer's disease earlier and more accurately keep emerging. One such test involves patients undergoing a spinal tap to provide a…
07/27/18Finding a cure for Alzheimer’s disease has proved elusive. The drugs currently on the market only manage the symptoms of cognitive decline, and the most…
07/06/18Proteinopathies, the misfolded proteins responsible for neuron deaths, have a claim to fame when it comes to rare neurodegenerative diseases.
The Center for Neurodegenerative Disease Research's Marian S. Ware Research Retreat
"The Molecular Biology of Aging and Neurodegeneration"
Thursday, October 25, 2018
8:30am — 4:10pm
Biomedical Research Building (BRB) II/III
421 Curie Blvd., Philadelphia PA 19104
© The Trustees of the University of Pennsylvania | Site best viewed in a supported browser. | Site Design: PMACS Web Team.